Updated on 13/07/2026

MATD3 Rede Mater Dei de Saúde

QuoteR$ 4,91
Dividend Yield3,07 %
P/E13,23
P/B1,09

Visno Score

AI-powered fundamental analysis
Powered by AI
Final score
4.5/ 10

Rentabilidade

  • ROE médio dos últimos 5 anos: 6,2%
  • ROIC médio dos últimos 5 anos: 9,3%

Liquidez

  • Liquidez corrente: 2,91x
  • Liquidez seca: 2,76x

Alavancagem

  • Dívida Líquida / EBITDA: 1,58x
  • Dívida Líquida/Patrimônio líquido: 0,52x

Consistência

  • Número de anos consecutivos sem prejuízo: 1 anos
  • Número de anos com lucro nos últimos 10 anos: 4 anos

Crescimento

  • CAGR receita líquida 5 anos: 0,0%

Negociabilidade

  • Porcentagem de ações em circulação: 17,2%
  • Volume diário de negociações: R$ 987K/dia

Fundamental Analysis of MATD3 (Rede Mater Dei de Saúde)

IA

Rede Mater Dei de Saúde is a company in the Healthcare sector, operating in the Medical Hospital Services, Testing and Diagnostics subsector and segment. With shares traded on B3 under the ticker MATD3, its core activity is operating a private hospital network focused on medical-hospital care and related services. The company is positioned in a capital- and service-intensive segment, typical of hospital networks, combining care infrastructure with a broad offering of medical specialties and diagnostics.

The reported financial fundamentals suggest a relatively profitable business by sector standards, with positive gross, EBIT, and net margins, as well as ROE and ROIC indicating the ability to generate returns on invested capital. Leverage, measured by Net Debt/EBITDA around 1.6, points to a moderate level of indebtedness, while current and quick ratios above 2.5 indicate ample capacity to meet short-term obligations. These figures should be interpreted alongside the cost and investment dynamics typical of the hospital sector.

The company obtained a 4.5 score on the Visno Score, reflecting a combination of good liquidity and comfortable leverage, but with lower scores in consistency and growth. Trading liquidity also appears limited, which may influence how MATD3 shares are used in investment strategies.

AI-generated analysis based on the Visno Score methodology. Data extracted from public financial statements (CVM/B3). Informational content — not investment advice.

MATD3 Price History

Daily
one_year

MATD3 Revenue vs. Profit

Anual

Valuation Indicators de MATD3

Valuation Indicators for MATD3 — annual indicator history
IndicatorCurrent20252024202320222021
Price R$ 4,91R$ 5,26R$ 3,47R$ 7,86R$ 6,73R$ 12,51
Price/Earnings (P/E) 13,2321,580,0026,9621,940,00
Price/Book Value (P/B) 1,091,200,881,921,563,13
Dividend Yield 3,07 %4,28 %2,16 %0,82 %1,34 %0,00 %
Price/Assets 0,380,400,290,620,531,91
Price/EBIT 4,315,730,007,449,020,00
Price/Net Revenue 0,730,840,571,481,730,00
Price/OCF 9,4614,487,4127,0834,240,00
Price/FCF 12,9025,310,000,000,000,00
EV/EBIT 6,378,060,009,6011,630,00
EV/EBITDA 4,895,900,007,898,730,00
EV/Net Revenue 1,071,170,881,912,230,00
EV/Assets 0,560,560,450,800,681,48
EV/OCF 13,9820,3511,3934,9244,140,00
EV/FCF 19,0535,560,000,000,000,00
Book Value per Share (BVPS) R$ 4,49R$ 4,39R$ 4,12R$ 4,35R$ 4,62R$ 4,31
Earnings per Share (EPS) R$ 0,37R$ 0,24R$ -0,89R$ 0,31R$ 0,33R$ 0,00
Market Cap R$ 1,64 BR$ 1,75 BR$ 1,30 BR$ 3,19 BR$ 2,56 BR$ 4,79 B
Enterprise Value (EV) R$ 2,42 BR$ 2,47 BR$ 2,00 BR$ 4,12 BR$ 3,30 BR$ 3,70 B
Daily Volume R$ 986,73 KR$ 978,03 KR$ 2,90 MR$ 3,33 MR$ 4,86 MR$ 11,32 M

Profitability Indicators de MATD3

Profitability Indicators for MATD3 — annual indicator history
IndicatorCurrent20252024202320222021
Gross Margin 30,28 %29,95 %30,13 %32,54 %35,35 %39,54 %
Net Margin 5,50 %5,08 %5,91 %6,40 %15,02 %
EBIT Margin 16,88 %16,26 %19,36 %19,16 %24,33 %
ROIC 13,21 %12,28 %14,08 %11,63 %8,40 %
ROE 8,26 %7,55 %7,81 %6,97 %8,84 %
ROA 2,86 %2,56 %2,50 %2,29 %3,54 %
Asset Turnover 0,52 %0,50 %0,51 %0,42 %0,36 %0,24 %

Liquidity Indicators de MATD3

Liquidity Indicators for MATD3 — annual indicator history
IndicatorCurrent20252024202320222021
Immediate Liquidity 1,071,221,330,470,562,89
Current Ratio 2,913,043,162,592,625,05
Quick Ratio 2,762,903,052,462,474,95
Total Liquidity Ratio 0,990,970,960,740,741,09

Leverage Indicators de MATD3

Leverage Indicators for MATD3 — annual indicator history
IndicatorCurrent20252024202320222021
Net Debt/EBIT 2,062,202,212,440,00
Net Debt/EBITDA 1,581,661,841,900,00
Net Debt/Equity 0,520,530,520,570,510,00
Gross Debt/Equity 0,910,960,980,760,740,68
Equity/Assets 0,350,340,330,320,330,40

Financial Results de MATD3

Financial Results for MATD3 — annual indicator history
IndicatorCurrent20252024202320222021
Net Revenue R$ 2,25 BR$ 2,18 BR$ 2,23 BR$ 2,19 BR$ 1,76 BR$ 964,63 M
Gross Profit R$ 681,55 MR$ 651,42 MR$ 670,60 MR$ 711,85 MR$ 623,19 MR$ 381,44 M
EBITDA R$ 494,20 MR$ 466,75 MR$ -301,26 MR$ 509,24 MR$ 434,23 MR$ 289,67 M
EBIT R$ 379,89 MR$ 353,73 MR$ -335,85 MR$ 423,61 MR$ 337,90 MR$ 234,74 M
Net Profit R$ 123,78 MR$ 110,51 MR$ -338,44 MR$ 129,19 MR$ 112,77 MR$ 144,92 M

Balance Sheet de MATD3

Balance Sheet for MATD3 — annual indicator history
IndicatorCurrent20252024202320222021
Assets R$ 4,33 BR$ 4,31 BR$ 4,34 BR$ 5,17 BR$ 4,93 BR$ 4,09 B
Liabilities R$ 2,84 BR$ 2,85 BR$ 2,89 BR$ 3,52 BR$ 3,32 BR$ 2,45 B
Shareholders' Equity R$ 1,50 BR$ 1,46 BR$ 1,45 BR$ 1,66 BR$ 1,62 BR$ 1,64 B
Cash and Equivalents R$ 556,80 MR$ 599,13 MR$ 622,58 MR$ 227,30 MR$ 246,41 MR$ 1,00 B
Inventories R$ 78,88 MR$ 71,78 MR$ 49,76 MR$ 63,16 MR$ 64,29 MR$ 35,34 M
Gross Debt R$ 1,36 BR$ 1,40 BR$ 1,42 BR$ 1,25 BR$ 1,20 BR$ 1,11 B
Net Debt R$ 781,02 MR$ 777,00 MR$ 747,61 MR$ 935,73 MR$ 824,88 MR$ -167,26 M
Short-Term Debt R$ 91,94 MR$ 112,33 MR$ 75,90 MR$ 52,20 MR$ 52,97 MR$ 64,05 M
Long-Term Debt R$ 1,27 BR$ 1,29 BR$ 1,35 BR$ 1,20 BR$ 1,15 BR$ 1,05 B

Cash Flow de MATD3

Cash Flow for MATD3 — annual indicator history
IndicatorCurrent20252024202320222021
OCF R$ 173,06 MR$ 224,33 MR$ 132,43 MR$ 157,21 MR$ 98,32 MR$ 91,28 M
ICF R$ 16,56 MR$ 13,78 MR$ 216,26 MR$ -164,67 MR$ -744,46 MR$ -1,24 B
Financing CF R$ -248,93 MR$ -261,56 MR$ 46,59 MR$ -11,65 MR$ -107,65 MR$ 1,96 B
CAPEX R$ -46,07 MR$ -47,57 MR$ -188,41 MR$ -154,47 MR$ -199,97 MR$ -108,56 M
FCF R$ 126,99 MR$ 176,76 MR$ -55,98 MR$ 2,74 MR$ -101,65 MR$ -17,27 M

Growth de MATD3

Growth for MATD3 — annual indicator history
IndicatorCurrent20252024202320222021
Net Revenue CAGR 5Y N/A
Net Profit CAGR 5Y N/A
EBIT CAGR 5Y N/A
EBITDA CAGR 5Y N/A

Target Price de MATD3

Target Price for MATD3 — annual indicator history
IndicatorCurrent20252024202320222021
Target Price - Graham R$ 6,13R$ 4,90R$ 0,00R$ 5,50R$ 5,84R$ 0,00

Registration Data de MATD3

Registration Data for MATD3 — annual indicator history
Sector Health Care
Subsector Hospitals & Diagnostics
Website N/A
Status Fase Operacional
Years Listed 5
CVM Code 25690
CNPJ 16.676.520/0001-59
Last Price Date 13/07/2026
Last Earnings Date 31/03/2026
Next Earnings Date 12/08/2026
Free Float 17,16 %
Other Tickers N/A

About Rede Mater Dei de Saúde

Rede Mater Dei de Saúde is a Brazilian company dedicated to providing hospital and oncology services, with common shares traded on B3 under the ticker MATD3. Its origins date back to 1973, when it was founded by physician José Salvador Silva in Belo Horizonte. The first hospital unit, Hospital Mater Dei Santo Agostinho, was opened in 1980, marking the beginning of a trajectory of expansion in clinical, technological, and infrastructure capacity. Throughout the 1980s, the institution consolidated itself as a reference in mastology, with the creation of Unimater, and in pediatric intensive care, by implementing one of the first pediatric ICUs in the state of Minas Gerais. In 1989, performing one of the first successful in vitro fertilizations in the country reinforced the company’s positioning in reproductive medicine.

In the 1990s and 2000s, Rede Mater Dei deepened the professionalization of its management and expanded its hospital structure. In 1992, it joined PAEX, a program by Fundação Dom Cabral focused on management excellence, and in 1994 it began clinical staff planning aligned with the corporate strategy. The physical expansion of the Santo Agostinho Unit, including Block II and the implementation of a Day Hospital, was accompanied by the creation of in-house clinical pathology labs, the expansion of diagnostic imaging services, and the structuring of research ethics committees. From 2000 onward, the company intensified clinical and administrative standardization with programs such as the Qualitas Project, which resulted in hundreds of medical protocols and nursing processes, contributing to the achievement of national and international quality certifications.

The evolution of Rede Mater Dei increasingly incorporated hospital accreditation standards and clinical governance. In 2004, the hospital achieved the highest level of the National Accreditation Organization (ONA III), becoming one of the first in Brazil to receive this recognition. Subsequently, it pursued international certifications such as ISO 9001, NIAHO, associated with the North American model of healthcare quality, and later the Joint Commission International (JCI) accreditation, obtained in 2016 by Mater Dei Contorno, the first hospital in Minas Gerais to receive this seal. In parallel, the company structured medical residency and health specialization programs, also consolidating itself as a training center for professionals, integrated into a governance model that combines executive managers and physicians.

Rede Mater Dei de Saúde’s business model is based on operating general hospitals, oncology units, outpatient clinics, and clinical laboratories on an integrated platform of medical-hospital services. The company operates exclusively in the hospital services segment, recognizing its revenue mainly from inpatient admissions, emergency room visits, surgeries, intensive care, oncology, diagnostic medicine, and outpatient services. The company offers more than 60 medical specialties across its units, structured to capture revenue in several links of the care chain, from imaging and lab tests to high-complexity procedures such as robotic surgeries, bone marrow transplants, and integrated oncology treatments. This model seeks economies of scale and operational efficiency, with strong protocol standardization and intensive use of clinical performance indicators.

In terms of its service portfolio, Rede Mater Dei operates inpatient units and adult and pediatric ICUs, surgical centers with dozens of operating rooms distributed across its units, 24-hour emergency rooms in multiple specialties, and proprietary outpatient clinics such as Mais Saúde, focused on continuous care and management of chronic patients. The oncology area is organized around the Integrated Cancer Hospital, designed for the exclusive care of oncology patients, with infrastructure that integrates clinical oncology, onco-hematology, pediatric oncology, oncogenetics, cardio-oncology, oncofertility, and bone marrow transplant, in addition to advanced imaging services such as PET-CT. The company also maintains a Human Reproduction Center with assisted reproduction technologies in a hospital environment, and a diagnostic medicine park that includes CT scanners, MRI equipment, mammography machines, hemodialysis devices, and other therapeutic and diagnostic support resources.

The geographic and operational expansion of Rede Mater Dei de Saúde has resulted in an approximate capacity of 2,200 hospital beds distributed across nine units, with around 1,200 operational beds. The company has consolidated a prominent position in Minas Gerais, especially in the metropolitan region of Belo Horizonte, with units such as Santo Agostinho, Contorno, and Betim-Contagem, and, starting in 2019, it began a cycle of national expansion with projects and acquisitions in other regions. Operations came to cover cities such as Salvador, Feira de Santana, Uberlândia, and Goiânia, expanding the patient base in different regional markets. The construction and acquisition of new hospitals, combined with ongoing investments in medical technology, have contributed to the increase in the number of beds since the IPO in 2021, when the company more than doubled its installed capacity.

From a commercial standpoint, Rede Mater Dei maintains relationships with several health plan operators, insurers, and self-managed entities, such as Bradesco Saúde, Sul América, Amil, Allianz, Cassi, pension companies, and corporate plans of large groups. Revenue shows some concentration, with the largest client accounting for a relevant share of net operating revenue, which makes contract management with health plan operators and administrators a central factor in the company’s economic dynamics. Operations are primarily aimed at middle- and high-income patients under supplemental health coverage, in a Brazilian market considered fragmented in terms of private hospital supply. Long-term relationships with operators and the maintenance of quality standards and hospital accreditations are important factors for the network’s inclusion and permanence in provider panels.

Rede Mater Dei de Saúde’s activities are strongly influenced by state regulation of the supplemental healthcare sector and health surveillance. The relationship with health plan operators is governed by rules from the National Supplementary Health Agency (ANS), which define parameters for coverage, readjustments, contracts between operators and providers, and rules for replacing providers in accredited networks. In addition, the operation of hospitals, clinics, laboratories, and diagnostic services depends on licenses and permits granted by health authorities, under the coordination of the National Health Surveillance Agency (ANVISA), which regulates aspects such as sanitary safety, handling of biological materials, disposal of hospital waste, and use of radioactive materials. Compliance with these regulatory requirements is a foundational element for the operational continuity of the services provided by the network.

Rede Mater Dei de Saúde’s management incorporates corporate governance practices aligned with the Novo Mercado listing segment, with a board of directors and structured family succession. From a care standpoint, the company operates with a focus on patient safety, monitoring clinical indicators through dashboards and committees involving the medical staff and executive board. The application of methodologies such as PDCA and the Quintuple Aim model from the Institute for Healthcare Improvement guides continuous improvement initiatives in care experience, population health, per capita cost, well-being of health workers, and equity. The company also invests in internal training and leadership programs, such as the Institutional Training Center and the Lidera Mater Dei program, and uses digital platforms, such as the Meu Mater Dei app, for scheduling appointments, tracking surgeries, and accessing test results, integrating technology into clinical care and patient journey management.

In the environmental, social, and governance (ESG) field, Rede Mater Dei de Saúde directs efforts toward efficient resource use and adherence to sustainable practices, such as entering the free energy market, enabling the use of renewable sources. From a social perspective, the company’s role stands out in training health professionals, offering residency and specialization programs, and adopting international patient safety protocols recommended by the World Health Organization and ANVISA. In governance, the combination of physician and non-physician managers, the structuring of boards, and adherence to corporate transparency standards reflect a model aimed at the longevity of the business and the professionalized management of one of the country’s main private hospital networks, with publicly traded capital and MATD3 shares listed on B3.

MATD3 Dividend History

Latest dividends paid by MATD3 — Dividends and Interest on Equity (JCP)
TypeEx-DateValue per Share
Dividendo08/12/2025R$ 0,15
Dividendo13/05/2025R$ 0,07
Dividendo30/04/2024R$ 0,07
Dividendo28/04/2023R$ 0,06
Dividendo29/04/2022R$ 0,09

Find new opportunities

Discover stocks with the best fundamentals

Latest News on MATD3

About Rede Mater Dei de Saúde

No news found

MATD3 indicator guide

What is MATD3's current price?

What is MATD3's Price today?

MATD3's Price is R$ 4,91 (13/07/2026).

What is Price and what does it indicate?

The stock's latest market price, representing the value at which it traded at the most recent close.

How should MATD3's Price be interpreted?

Price changes reflect shifts in market expectations; monitoring them alongside other indicators helps identify opportunities and risks.

What can affect MATD3's Price?

It is influenced by the company's financial performance, market news, macroeconomic conditions, and investor sentiment.

MATD3's P/E: is the stock expensive or cheap?

What is MATD3's Price/Earnings (P/E) today?

MATD3's Price/Earnings (P/E) is 13,23 (13/07/2026).

What is Price/Earnings (P/E) and what does it indicate?

Price/Earnings relates the stock's market price to earnings per share, showing how much investors are willing to pay for the company's earnings.

How should MATD3's Price/Earnings (P/E) be interpreted?

A high P/E generally suggests strong expectations for future growth, while a low P/E may indicate an undervalued stock or operating challenges.

What can affect MATD3's Price/Earnings (P/E)?

This indicator is influenced by operating results, earnings growth, macroeconomic conditions, and investor expectations, and varies across the economic cycle.

MATD3's P/B: what it reveals about valuation

What is MATD3's Price/Book Value (P/B) today?

MATD3's Price/Book Value (P/B) is 1,09 (13/07/2026).

What is Price/Book Value (P/B) and what does it indicate?

Price/Book Value per Share relates the stock's market price to book value per share, showing how much investors pay for the company's equity.

How should MATD3's Price/Book Value (P/B) be interpreted?

A P/B below 1 may signal an undervalued stock, while a high value may reflect expectations of future appreciation or risks related to asset quality.

What can affect MATD3's Price/Book Value (P/B)?

Capital structure, the share of intangible assets, reinvestment policies, and economic conditions significantly affect book value.

MATD3's Dividend Yield: how much does it pay in dividends?

What is MATD3's Dividend Yield today?

MATD3's Dividend Yield is 3,07 % (13/07/2026).

What is Dividend Yield and what does it indicate?

Dividend Yield is the percentage relationship between dividends paid to shareholders and the current stock price, showing the return received as dividends.

How should MATD3's Dividend Yield be interpreted?

A high Dividend Yield may indicate an income opportunity, but it should be assessed alongside earnings stability and the consistency of dividend distributions over time.

What can affect MATD3's Dividend Yield?

The company's dividend policy, financial results, cash flow, and capital allocation strategies are key drivers of Dividend Yield.

MATD3's EV/EBITDA: valuation accounting for debt

What is MATD3's EV/EBITDA today?

MATD3's EV/EBITDA is 4,89 (13/07/2026).

What is EV/EBITDA and what does it indicate?

EV/EBITDA relates enterprise value to EBITDA, highlighting operating cash-generation capacity before depreciation and amortization.

How should MATD3's EV/EBITDA be interpreted?

A low value may suggest an attractive valuation, while a high value may indicate an expensive valuation or weak operating cash generation.

What can affect MATD3's EV/EBITDA?

Depreciation policies, investments, and operating efficiency influence EBITDA.

MATD3's BVPS: what is the book value per share?

What is MATD3's Book Value per Share (BVPS) today?

MATD3's Book Value per Share (BVPS) is R$ 4,49 (13/07/2026).

What is Book Value per Share (BVPS) and what does it indicate?

Book Value per Share is the accounting value assigned to each share, reflecting the company's equity on a per-share basis.

How should MATD3's Book Value per Share (BVPS) be interpreted?

A low Book Value per Share may indicate an undervalued stock, while a high value may suggest the stock is expensive on an accounting basis.

What can affect MATD3's Book Value per Share (BVPS)?

Asset revaluations, retained earnings, and dividend policies influence Book Value per Share.

MATD3's EPS: how much profit per share?

What is MATD3's Earnings per Share (EPS) today?

MATD3's Earnings per Share (EPS) is R$ 0,37 (13/07/2026).

What is Earnings per Share (EPS) and what does it indicate?

Earnings per Share is net income divided by the total number of shares, indicating the earnings attributable to each share.

How should MATD3's Earnings per Share (EPS) be interpreted?

Rising Earnings per Share is a positive profitability signal, while a decline may indicate challenges in generating earnings.

What can affect MATD3's Earnings per Share (EPS)?

Operating efficiency, cost management, and changes in net income influence Earnings per Share.

MATD3's Market Cap: how much is the company worth on the exchange?

What is MATD3's Market Cap today?

MATD3's Market Cap is R$ 1,64 B (13/07/2026).

What is Market Cap and what does it indicate?

Market capitalization is the company's total market value, calculated by multiplying the share price by the number of shares outstanding.

How should MATD3's Market Cap be interpreted?

A high market capitalization may indicate an established company, while a low value may point to growth opportunities or greater volatility.

What can affect MATD3's Market Cap?

Share price, share count, and market conditions influence market capitalization.

MATD3's Net Margin: how much profit is left per dollar sold?

What is MATD3's Net Margin today?

MATD3's Net Margin is 5,50 % (13/07/2026).

What is Net Margin and what does it indicate?

Net Margin is net income as a percentage of net revenue, showing the company's effective profitability.

How should MATD3's Net Margin be interpreted?

High margins indicate efficient conversion of revenue into profit, while low margins may signal challenges.

What can affect MATD3's Net Margin?

Cost management, operating expenses, and the tax burden influence Net Margin.

MATD3's ROIC: the return on invested capital

What is MATD3's ROIC today?

MATD3's ROIC is 13,21 % (13/07/2026).

What is ROIC and what does it indicate?

ROIC (Return on Invested Capital) measures the return earned on all capital invested in the company, reflecting how efficiently resources are used.

How should MATD3's ROIC be interpreted?

A high ROIC suggests efficient use of resources, while a low ROIC may indicate inefficient capital allocation.

What can affect MATD3's ROIC?

Investment strategies, operating efficiency, and capital structure influence ROIC.

MATD3's ROE: is the company efficient at generating profit?

What is MATD3's ROE today?

MATD3's ROE is 8,26 % (13/07/2026).

What is ROE and what does it indicate?

ROE (Return on Equity) measures the return on shareholders' equity, reflecting profitability for shareholders.

How should MATD3's ROE be interpreted?

A high ROE is generally positive, but it should be assessed together with the company's capital structure.

What can affect MATD3's ROE?

Operating management, dividend policy, and financial leverage influence ROE.

MATD3's Net Debt/EBITDA: is the debt level healthy?

What is MATD3's Net Debt/EBITDA today?

MATD3's Net Debt/EBITDA is 1,58 (13/07/2026).

What is Net Debt/EBITDA and what does it indicate?

Net Debt/EBITDA assesses the company's ability to repay debt with cash generated by operations, before depreciation and amortization.

How should MATD3's Net Debt/EBITDA be interpreted?

Low values indicate greater financial safety, while high values may signal excessive debt risk.

What can affect MATD3's Net Debt/EBITDA?

Capital structure, operating efficiency, and investments influence EBITDA.

Frequently Asked Questions about MATD3

What is MATD3's stock price today?

MATD3's price on 13/07/2026 is R$ 4.91. The price is updated based on the latest data available from B3.

Does MATD3 pay dividends?

Over the last 12 months, MATD3 paid dividends and/or JCP in December, totaling R$ 0.15 per share (Dividend Yield of 3.07%). Payments depend on results and decisions made by the board of directors.

How do I buy MATD3 shares?

To buy MATD3 (Rede Mater Dei de Saúde) shares, you need an account with a brokerage that has access to B3. After that, just search for the ticker MATD3 and place a buy order through the brokerage's platform.

How do I analyze MATD3 stock?

To analyze MATD3, consider indicators such as P/E of 13.23, Dividend Yield of 3.07%, ROE of 8.26%, net margin of 5.50%. The evaluation should include comparison with companies in the same sector and the company's financial history.